investor fraud

Richtech Robotics faces securities class action after Microsoft denied partnership, stock crashed 20% following 30% surge on alleged false collaboration announcement.

Trip.com shares crater 17% after Chinese regulators investigate alleged anticompetitive AI pricing tool. Securities lawsuit filed; company shuts down tool.

EOSE shares plunged 39% after missing FY 2025 revenue targets by 25% and revealing manufacturing delays. Securities lawsuit alleges management concealed production issues from investors.

$EOSE plummeted 39% after revealing 25% FY2025 revenue shortfall and production problems. Securities lawsuit alleges management concealed scaling issues from investors.

Trip.com shares crater 17% amid Chinese anti-monopoly investigation into allegedly coercive AI pricing tool. Securities class action filed; tool shut down, co-founders resign.

Rosen Law Firm seeks lead plaintiffs in securities class action against Corcept Therapeutics, alleging misrepresentation of FDA communications and clinical trial data for relacorilant drug.

Snowflake faces securities class action alleging failure to disclose how product efficiency improvements would materially harm consumption-based revenue model.

Rosen Law Firm alerts investors in multiple securities litigation cases, including $PMI, urging them to secure counsel before critical claim deadlines.

PayPal faces securities class action after Q4 earnings miss, $9B market cap wipeout, and CEO departure. Branded Checkout growth collapsed to 1%.

Robbins LLP launches class action against $SLNO over alleged investor deception regarding DCCR drug safety and efficacy for Prader-Willi syndrome treatment.

PayPal faces class action lawsuit after Q4 earnings disappointed, stock plunged 20%, erasing $9B in market value. CEO departed.

$SLNO faces securities lawsuit alleging misleading safety claims for hyperphagia drug VYKAT XR. Stock crashed 40% after short seller report and management admissions of launch disruptions.

Richtech Robotics faces securities lawsuit after overstating Microsoft partnership, causing 30% stock surge followed by 20% decline when Microsoft clarified limited engagement.

Robbins LLP files class action suit against Agilon Health for allegedly issuing unachievable 2025 guidance and overstating strategic initiatives, following 50% stock decline.

Rosen Law Firm sues Ultragenyx for securities fraud, alleging executives misrepresented drug efficacy. Investors who bought stock August 2023-December 2025 can claim damages by April 6, 2026 deadline.